Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
Kardiologiia ; (S5): 20-29, 2018.
Artículo en Ruso | MEDLINE | ID: mdl-29894673

RESUMEN

PURPOSE OF THE STUDY: To compare the effect of loading doses of atorvastatin and rosuvastatin on the value of the acute kidney injury and acute inflammatory response to elective percutaneous coronary interventions. MATERIALS AND METHODS: An open prospective comparative study included 68 patients referred for elective percutaneous coronary intervention (PCI). At baseline, all patients had been taking statins for a long time as a standard lipid-lowering therapy. The first group included 33 patients who received a loading dose of 80 mg of atorvastatin (As) 12 hours before the intervention with saving this dose for 2-6 days. The second group included 35 patients treated with rosuvastatin (Rs) 40 mg / day in the same manner. The levels of creatinine and cystatin C in the blood were determined at baseline and 12, 24, 48 and 72 hours after the intervention. HsCRP level was determined at baseline and 72 hours after PCI. RESULTS: AKI was diagnosed in 5 patients (7.94 %): 4 patients (12.1 %) in group As and 1 patient (3.3 %) in group Rs (p = 0.36). The increase of serum creatinine level in the group As patients was 43.4 % higher than one in the Rs group patients (p = 0.024). The decrease of glomerular filtration rate (GFR) in group As was 15.5 % higher than one in group Rs (p = 0.09). Initially, the level of cystatin C in the groups did not differ (698.9 (560.2-869.6) ng / ml in group As vs 759.5 (673.8-899.9) ng/ml in group Rs, p = 0.75). Significant intergroup differences were found in the level of serum cystatin C 12 hours after PCI (718.3 (555.6-839.6) ng/ml in group As vs 470.6 (378.2-689.4) ng/ml in the Rs group, p = 0.007) that persisted 24 hours after the intervention (732.1 (632.3-887) ng/ml vs 526.4 (357.4-802.7) ng/ml, respectively, p = 0.02). From the second day after PCI, intergroup differences in serum cystatin C disappeared. The level of hsCRP significantly increased 72 hours after the intervention in group As (1.65 (0.9-4) mg/l at baseline vs 4.55 (1.6-8.7) mg/l 72 hours after PCI, p = 0.01). The level of hsCRP did not change significantly at the same time in the Rs group (2.8 (0.8-6.8) mg/l at baseline vs 2.75 (1.5-6.5) mg/l 72 hours after PCI, p = 0.16). CONCLUSION: The loading dose of rosuvastatin better prevents periprocedural kidney injury in PCI and more significantly reduces the overall inflammatory response to intervention compared to the loading dose of atorvastatin.


Asunto(s)
Inhibidores de Hidroximetilglutaril-CoA Reductasas , Intervención Coronaria Percutánea , Humanos , Estudios Prospectivos
2.
Bull Exp Biol Med ; 164(3): 316-319, 2018 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-29308566

RESUMEN

The role of JAK/STAT3-mediated signaling pathway in the realization of the growth potential of mesenchymal precursor cells was examined in vitro. The stimulating role of JAKs and STAT3 towards proliferating activity of progenitor cells and their different role in the regulation of differentiation of the progenitor elements were demonstrated. Inhibitors of JAKs and STAT3 reduced the yield of fibroblast CFU and their mitotic activity. Blockade of JAKs accelerated and selective inactivation of STAT3 decelerated differentiation of progenitor cells.


Asunto(s)
Células de la Médula Ósea/metabolismo , Fibroblastos/metabolismo , Janus Quinasa 1/genética , Janus Quinasa 3/genética , Células Madre Mesenquimatosas/metabolismo , Factor de Transcripción STAT3/genética , Animales , Antraquinonas/farmacología , Células de la Médula Ósea/citología , Células de la Médula Ósea/efectos de los fármacos , Diferenciación Celular/efectos de los fármacos , Proliferación Celular/efectos de los fármacos , Fibroblastos/citología , Fibroblastos/efectos de los fármacos , Regulación de la Expresión Génica , Janus Quinasa 1/antagonistas & inhibidores , Janus Quinasa 1/metabolismo , Janus Quinasa 3/antagonistas & inhibidores , Janus Quinasa 3/metabolismo , Células Madre Mesenquimatosas/citología , Células Madre Mesenquimatosas/efectos de los fármacos , Ratones , Ratones Endogámicos C57BL , Nitrilos , Fosforilación , Cultivo Primario de Células , Pirazoles/farmacología , Pirimidinas , Factor de Transcripción STAT3/antagonistas & inhibidores , Factor de Transcripción STAT3/metabolismo , Transducción de Señal , Sulfonamidas/farmacología
3.
Bull Exp Biol Med ; 164(1): 10-14, 2017 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-29124537

RESUMEN

A cross-sectional study of universe sample of patients (N=135; mean age -49.7±0.8 years) with metabolic syndrome yielded the incidence of cardiac autonomic neuropathy of 37.5%. The pathogenetic peculiarities were revealed for the onset and development of this neuropathy. At the early stages, the progress of cardiac autonomic neuropathy closely correlated with elevation of blood glucose, while endothelial dysfunction progressing at the later period against the background of persistent hyperglycemia is viewed as an extra factor contributing to the development of this disease.


Asunto(s)
Síndrome Metabólico/patología , Enfermedades del Sistema Nervioso Periférico/patología , Adulto , Sistema Nervioso Autónomo/patología , Sistema Nervioso Autónomo/fisiopatología , Glucemia , Estudios Transversales , Femenino , Frecuencia Cardíaca , Humanos , Masculino , Síndrome Metabólico/sangre , Síndrome Metabólico/fisiopatología , Persona de Mediana Edad , Enfermedades del Sistema Nervioso Periférico/sangre , Enfermedades del Sistema Nervioso Periférico/fisiopatología , Factores de Riesgo , Volumen Sistólico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...